Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Molecular Structure: Comprehensive Analysis Of Cross-Linked Carboxymethylcellulose Architecture And Functional Properties

NOV 17, 202657 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium represents an internally cross-linked derivative of sodium carboxymethylcellulose, engineered through controlled pH reduction and thermal treatment during manufacturing to create a three-dimensional polymeric network. This pharmaceutical excipient exhibits unique fibrous morphology with particle sizes predominantly below 44.5 μm, maintaining structural integrity upon water absorption without forming pasty gels—a critical distinction from its non-cross-linked precursor 12. The cross-linked architecture confers exceptional disintegration, wicking, and moisture management properties, establishing croscarmellose sodium as a superdisintegrant of choice in solid dosage formulations across global pharmacopeias 34.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Cross-Linking Chemistry Of Croscarmellose Sodium

Croscarmellose sodium is synthesized from sodium carboxymethylcellulose (NaCMC) through an intramolecular cross-linking process that fundamentally alters its physicochemical behavior 14. The parent polymer, sodium carboxymethylcellulose, consists of a cellulose backbone wherein hydroxyl groups are partially substituted with carboxymethyl (-CH₂COONa) moieties, typically achieving a degree of substitution (DS) ranging from 0.60 to 0.90 415. This substitution pattern is critical: formulations targeting pharmaceutical-grade croscarmellose sodium preferentially employ NaCMC with DS values between 0.80–0.90 to balance solubility suppression and reactive site availability 4.

The cross-linking mechanism proceeds via esterification under acidic catalysis. During manufacture, the pH of an aqueous or aqueous-organic suspension of NaCMC is reduced to 1.0–4.0 using mineral acids such as sulfuric acid (15%–30% w/w) or hydrochloric acid, followed by controlled heating at 40–75°C for 0.5–4.0 hours 1412. Under these conditions, carboxyl groups on adjacent polymer chains undergo intermolecular esterification, forming covalent cross-links that create a three-dimensional network 115. Patent literature describes a two-stage thermal protocol: initial reaction at 40–50°C for 0.5–2.0 hours, then elevation to 65–75°C for 2.0–4.0 hours, optimizing cross-link density while minimizing chain degradation 4. Alternative methods employ propylene glycol as a bifunctional cross-linking agent under similar acidic conditions, though self-cross-linking via direct esterification remains the dominant industrial route 1.

Key structural features distinguishing croscarmellose sodium from NaCMC include:

  • Insolubility in water: Cross-linking suppresses the polymer's ability to dissolve, instead promoting rapid swelling (up to 4–8 times original volume) while preserving particle discreteness 211.
  • Fibrous morphology: The cross-linked network retains the native cellulose fibril architecture, with 90% of particles measuring ≤44.5 μm and exhibiting high aspect ratios conducive to capillary wicking 211.
  • Enhanced mechanical resilience: Cross-links impart elastic recovery upon compression, a property absent in linear NaCMC, which forms viscous gels 213.

The stoichiometry of cross-linking is governed by the initial DS, acid concentration, temperature, and reaction duration. Over-cross-linking (excessive heating or prolonged acidification) yields brittle, poorly swelling materials, whereas under-cross-linking results in residual solubility and gelling tendencies 415. Optimal formulations achieve a balance where 10–30% of carboxyl groups participate in cross-links, as inferred from swelling volume measurements (typically 5–12 mL/g for pharmacopeial grades) 115.

Particle Size Distribution And Surface Area Characteristics

Particle size distribution (PSD) is a critical quality attribute influencing the disintegration kinetics and compaction behavior of croscarmellose sodium. Standard pharmaceutical grades exhibit a median particle size (D₅₀) of 25–50 μm, with 90% of particles (D₉₀) below 80–100 μm 1118. Recent innovations have introduced fine-particle variants with D₅₀ values of 5–36 μm and volume mean diameters (D[4,3]) ≤40 μm, designed to enhance disintegration at elevated use levels (≥4% w/w) 1118.

Comparative PSD data from patent disclosures reveal:

  • Conventional croscarmellose sodium (e.g., Ac-Di-Sol® standard grade): D₅₀ = 34 μm, D₁₀ = 8–12 μm, D₉₀ = 70–90 μm 18.
  • Fine-particle croscarmellose sodium: D₅₀ = 15–25 μm, D₁₀ ≤15 μm, D₉₀ ≤80 μm, with specific surface areas ≥0.3 m²/g 11.
  • Coarse-particle experimental grades: D₅₀ = 59–86 μm, developed to reduce disintegration time variability under high compaction forces (>15 kN) 18.

The specific surface area (SSA) of croscarmellose sodium, measured by BET nitrogen adsorption, typically ranges from 0.3 to 1.2 m²/g, significantly lower than highly porous superdisintegrants like crospovidone (SSA ~1.5–2.5 m²/g) 11. However, the fibrous morphology compensates for modest SSA by facilitating rapid liquid penetration via capillary action along fiber axes 213. Scanning electron microscopy (SEM) confirms that croscarmellose sodium particles consist of aggregated microfibrils (0.5–2 μm diameter) with interstitial voids, creating a tortuous pore network that enhances wicking efficiency 2.

Particle size optimization is application-dependent:

  • Low-dose tablets (<2% croscarmellose sodium): Fine particles (D₅₀ <25 μm) maximize surface area contact with the active pharmaceutical ingredient (API), accelerating disintegration to <30 seconds in USP Apparatus 1 (basket method, 37°C, pH 6.8 phosphate buffer) 1113.
  • High-dose formulations (≥4% croscarmellose sodium): Coarser particles (D₅₀ >56 μm) mitigate the "gelling plateau" effect observed at elevated concentrations, where excessive fine particles impede water ingress due to localized viscosity increases 18.
  • Direct compression applications: Intermediate PSD (D₅₀ = 30–50 μm) balances flowability (angle of repose <35°) and compactibility (tensile strength >2 MPa at 150 MPa compaction pressure) 415.

Synthesis Routes And Process Parameters For Croscarmellose Sodium Production

Industrial synthesis of croscarmellose sodium employs either aqueous or solvent-mediated cross-linking protocols, each offering distinct advantages in controlling reaction kinetics and product purity.

Aqueous Cross-Linking Method

The aqueous route suspends NaCMC (DS 0.80–0.90) in deionized water at 5–15% w/v solids content, followed by acidification to pH 2.0–4.0 using sulfuric acid (15%–30% w/w) 412. The suspension is heated to 40–50°C under continuous agitation (200–400 rpm) for 0.5–2.0 hours, then ramped to 65–75°C for an additional 2.0–4.0 hours 4. Upon completion, the reaction mixture is neutralized with saturated sodium bicarbonate solution (pH 6.0–8.0), filtered, and the filter cake washed sequentially with water and 60% ethanol to remove residual salts 415. Final drying at 70–90°C under vacuum (<50 mbar) yields a free-flowing powder with residual moisture <5% 4.

Critical process parameters include:

  • Acid concentration: Higher sulfuric acid levels (25%–30%) accelerate cross-linking but risk over-esterification and chain scission; 15%–20% concentrations provide optimal control 412.
  • Temperature profile: The two-stage heating protocol minimizes thermal degradation while ensuring uniform cross-link distribution; single-stage heating at 70°C for 3 hours produces heterogeneous products with bimodal swelling behavior 4.
  • Neutralization timing: Premature neutralization (before cross-linking completion) leaves unreacted carboxyl groups, causing residual water solubility; delayed neutralization (>30 minutes post-reaction) promotes hydrolytic cleavage of ester cross-links 15.

Solvent-Mediated Cross-Linking Method

The solvent method disperses NaCMC in a water-miscible organic solvent (e.g., ethanol, isopropanol) at a 10:1 v/v solvent-to-water ratio, reducing the dielectric constant and suppressing ionization of carboxyl groups 415. Acidification to pH 2.0–3.0 with sulfuric acid initiates cross-linking at 40–50°C for 1.0–2.0 hours, followed by heating to 65–75°C for 2.0–3.0 hours 4. The use of organic solvents offers several advantages:

  • Enhanced reaction selectivity: Lower water activity shifts the esterification equilibrium toward cross-link formation, reducing side reactions such as carboxyl protonation and salt formation 4.
  • Improved product purity: Organic solvents facilitate removal of sodium sulfate byproduct via differential solubility, eliminating the need for extensive aqueous washing 412.
  • Reduced drying time: Ethanol co-evaporation during vacuum drying (70–90°C, <50 mbar) accelerates moisture removal, shortening batch cycle times by 20%–30% 4.

A representative solvent-mediated protocol from patent CN101580565B specifies: 100 g NaCMC (DS 0.85) dispersed in 1000 mL ethanol/water (10:1 v/v), acidified to pH 2.5 with 50 mL 20% H₂SO₄, heated at 45°C for 1.5 hours then 70°C for 2.5 hours, neutralized with Na₂CO₃ to pH 7.0, filtered, washed twice with 60% ethanol, and dried at 80°C for 6 hours 4. This process yields croscarmellose sodium with swelling volume 8.5 mL/g, particle size D₅₀ = 38 μm, and purity >99.5% (HPLC-CAD assay) 417.

Alternative Cross-Linking Agents

While self-cross-linking via direct esterification dominates commercial production, bifunctional reagents such as propylene glycol, epichlorohydrin, and divinyl sulfone have been explored to modulate cross-link density 1. Propylene glycol-mediated cross-linking proceeds under milder conditions (pH 1.5–3.0, 50–60°C, 2–4 hours), producing materials with higher elastic moduli (compression recovery >85% vs. 70% for acid-catalyzed products) but lower swelling capacities (6–7 mL/g) 1. Epichlorohydrin cross-linking, common in superabsorbent polymer synthesis, is avoided in pharmaceutical applications due to residual toxicity concerns (epichlorohydrin is a Class 2 solvent per ICH Q3C guidelines, with a permitted daily exposure limit of 0.6 mg/day) 1.

Physicochemical Properties: Swelling, Wicking, And Disintegration Mechanisms

The superdisintegrant functionality of croscarmellose sodium arises from three synergistic mechanisms: capillary wicking, volumetric swelling, and elastic recovery 213. Understanding these mechanisms at a molecular level is essential for optimizing formulation performance.

Capillary Wicking

The fibrous morphology of croscarmellose sodium creates a network of interparticle and intraparticle capillaries (pore diameters 0.1–5 μm) that rapidly draw aqueous media into tablet matrices via capillary action 213. The Washburn equation describes the kinetics of liquid penetration:

L² = (γ · r · t · cos θ) / (2η)

where L is penetration depth, γ is surface tension, r is capillary radius, t is time, θ is contact angle, and η is liquid viscosity 2. Croscarmellose sodium exhibits a low contact angle with water (θ ≈ 20°–30°), facilitating rapid wetting 13. Time-lapse video microscopy of tablet disintegration reveals that water ingress via croscarmellose sodium fibers precedes bulk swelling by 2–5 seconds, creating internal hydraulic pressure that fractures the tablet matrix 2.

Volumetric Swelling

Upon water absorption, croscarmellose sodium particles swell 4–8 times their original volume (swelling index 5–12 mL/g per USP <701> method) while maintaining structural integrity 12. This behavior contrasts sharply with non-cross-linked NaCMC, which dissolves to form a viscous gel (apparent viscosity >1000 cP at 1% w/v, 25°C) 2. The cross-linked network constrains polymer chain mobility, preventing dissolution while permitting osmotic water uptake into the hydrophilic carboxymethyl domains 213.

Swelling kinetics follow a pseudo-second-order model:

t/Q_t = 1/(k · Q_e²) + t/Q_e

where Q_t is water uptake at time t, Q_e is equilibrium uptake, and k is the swelling rate constant 2. For standard-grade croscarmellose sodium (D₅₀ = 34 μm), typical parameters are Q_e = 8.2 g/g, k = 0.15 g/(g·min) in deionized water at 37°C 2. Fine-particle grades (D₅₀ = 20 μm) exhibit faster kinetics (k = 0.22 g/(g·min)) due to higher surface area, but lower equilibrium uptake (Q_e = 7.1 g/g) attributed to increased cross-link density required to maintain particle discreteness at smaller sizes 11.

Elastic Recovery

Compression of croscarmellose sodium during tableting induces reversible deformation of the fibrous network, storing elastic energy that contributes to disintegration upon rehydration 213. Dynamic mechanical analysis (DMA) of compacted croscarmellose sodium reveals a storage modulus (E') of 1.2–1.8 GPa at 1 Hz, 25°C, with a loss tangent (tan δ) of 0.08–0.12, indicative of predominantly elastic behavior 2. Upon water contact, the modulus drops to 50–100 MPa within 10 seconds as hydration plasticizes the network, releasing stored strain energy that propagates microcracks through the tablet 213.

The relative contribution of each mechanism varies with formulation composition:

  • Low-dose tablets (<100 mg API, <2% croscarmellose sodium): Wicking dominates, with disintegration times <30 seconds driven by rapid water penetration 13.
  • High-dose tablets (>500 mg API, 4%–8% croscarmellose sodium): Swelling becomes rate-limiting, as the increased excipient mass requires greater water uptake to generate sufficient internal pressure; disintegration times extend to 60–120 seconds 678.
  • Highly compacted tablets (>200 MPa compaction pressure): Elastic recovery plays a critical role, as densification reduces porosity and impedes wicking; formulations with coarser croscarmellose sodium (D₅₀ >56 μm) maintain faster disintegration (45–60 seconds) compared to fine particles (90–150 seconds) under these conditions 18.
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONLow-dose and high-dose pharmaceutical tablets requiring rapid disintegration, particularly solid dosage forms with elevated superdisintegrant levels (≥4% w/w) where conventional grades exhibit reduced functionality.Ac-Di-Sol®Fine particle croscarmellose with median particle size 5-36 μm and specific surface area ≥0.3 m²/g, achieving disintegration time <30 seconds at ≥4% w/w concentration through enhanced capillary wicking and rapid swelling (4-8 times original volume).
ANHUI SHANHE PHARMACEUTICAL EXCIPIENTS CO. LTD.Industrial-scale production of pharmaceutical excipients for tablet disintegration applications, particularly for formulations requiring controlled cross-link density and high purity standards compliant with pharmacopeial requirements.Pharmaceutical-grade Croscarmellose SodiumSolvent-mediated cross-linking process using 10:1 ethanol/water ratio at pH 2-4 and 65-75°C, producing croscarmellose with swelling volume 8.5 mL/g, particle size D₅₀=38 μm, and purity >99.5%, with 20-30% reduced drying time compared to aqueous methods.
COMBE INCORPORATEDTopical body powder applications requiring superior moisture absorption for skin protection against wetness and irritation, particularly in personal care products where cosmetic feel and appearance are critical.Body Powder CompositionCroscarmellose sodium at 2-20% w/w concentration absorbs ≥20% moisture by weight while maintaining fibrous particle integrity without forming pasty gels, providing enhanced moisture absorbency with acceptable tactile sensation when combined with talc or starch diluents.
F. HOFFMANN-LA ROCHE AGSolid oral dosage forms containing active pharmaceutical ingredients requiring controlled disintegration kinetics, particularly tablets with 40-60% w/w API content subjected to high compaction pressures (>150 MPa) in direct compression manufacturing.Pharmaceutical Tablet FormulationCroscarmellose sodium at 5-10% w/w (optimally 5-7%) combined with hygroscopic polymeric excipients (hydroxypropylmethyl cellulose, microcrystalline cellulose, micronized crospovidone) totaling 44-50% w/w, achieving stable drug release through synergistic disintegration mechanisms of wicking, swelling and elastic recovery.
ORION CORPORATIONOral pharmaceutical tablets containing catechol derivatives (entacapone, nitecapone) for Parkinson's disease treatment, where rapid drug release and bioavailability are critical therapeutic requirements.Catechol Derivative TabletsCroscarmellose sodium at 8-16% w/w (especially 10-14%) substantially increases release rate of entacapone or nitecapone from compacted tablets through accelerated disintegration via capillary wicking and volumetric swelling mechanisms specific to the fibrous cross-linked cellulose structure.
Reference
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Body powder composition
    PatentInactiveUS6143285A
    View detail
  • Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid
    PatentInactiveHK1069772A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png